Recent Updates
Recently added Catalysts

Test 1= ASA and pantoprazole formulation one

Phase 1

Ulcers, Duodenal and Gastric | Small molecule | Gastrointestinal |GSK plc|Last Updated: Jul 13, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials2
Total Enrollment48

FDA Designations

No designations recorded

Clinical trial landscape

Test 1= ASA and pantoprazole formulation one · 2 trials · 1 indication

Phase 1 2
NCT01847417Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed ConditionsUlcers, Duodenal and Gastric
COMPLETED24 Analytics
NCT01847404Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting ConditionsUlcers, Duodenal and Gastric
COMPLETED24 Analytics
PHASE1COMPLETED
Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions
Ulcers, Duodenal and GastricUnlock trial analytics
PHASE1COMPLETED
Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions
Ulcers, Duodenal and GastricUnlock trial analytics

Study Endpoints

Primary Endpoints

Composite of pharmacokinetic (PK) parameters
During each period at pre-dose, 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 14, 16 and 24 hrs post dose

The bioavailability of two test products was compared with the reference products after determining the plasma PK parameters: Cmax (maximum measured plasma concentration), Tmax (time of Cmax), AUC0-t (area under the plasma concentration versus time curve from time zero to the last measurable concentration), AUC0-infinity (AUC from zero to infinity), t1/2 (time required for the plasma drug concentration to decrease by one half), Kel (terminal rate constant) and AUC\_% Extrap\_Obs (residual area in percentage determined by formula) for ASA and pantoprazole in relevant treatments

Secondary Endpoints

Tolerability of combined ASA and pantoprazole in subjects during the study
Up to 16 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Overall Study ArmEXPERIMENTALAll the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet

Interventions

NameTypeDescription
Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation oneDRUGFormulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation twoDRUGFormulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
ASA 100 mg tabletDRUGAspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
Pantoprazole 20 mg gastro-resistant tabletDRUGProtium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion criteria: * Healthy human subjects within the age range of 18 to 45 years (both inclusive) * Non-smokers since at least six months * Willingness to provide written informed consent to participate in the study * Body-mass index (BMI) of \>=18.5 kilogram per meter square (kg/m\^2) and \<=24...

Countries:India
Unlock Eligibility Criteria